NewsBenzinga주웻-카메론 트레이딩, 4분기 주당순손실 0.10달러로 전년 동기 0.64달러 대비 감소, 매출 767만 5천 달러로 전년 동기 1,037만 1천 달러 대비 감소 주웻-카메론 트레이딩, 4분기 주당순손실 0.10달러로 전년 동기 0.64달러 대비 감소, 매출 767만 5천 달러로 전년 동기 1,037만 1천 달러 대비 감소 Benzinga 2026.11.20 05:41 (GMT+0) Open on Benzinga Other news Geospace Technologies (GEOS) Shares Tumble 16.47% After Hours: Here's Why Stock Market: Will S&P 500 Open Up or Down Today? Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY ‘War of Necessity’: Trump Gets Senate Backing to Continue Fighting as Democrats Fail to Block Further Military Strikes Reported Earlier, Jewett-Cameron Trading Q4 EPS $(0.10) Up From $(0.64) YoY, Sales $7.675M Down From $10.371M YoY Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303
Update: Geospace Technologies Q4 Adj. EPS $(0.86) Down From $(0.71) YoY, Sales $19.589M Down From $30.714M YoY
‘War of Necessity’: Trump Gets Senate Backing to Continue Fighting as Democrats Fail to Block Further Military Strikes
Reported Earlier, Jewett-Cameron Trading Q4 EPS $(0.10) Up From $(0.64) YoY, Sales $7.675M Down From $10.371M YoY
Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303